Compare ETW & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest
Current Price
| Metric | ETW | TNDM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2005 | 2013 |
| Metric | ETW | TNDM |
|---|---|---|
| Price | $9.25 | $16.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 25 |
| Target Price | N/A | ★ $27.76 |
| AVG Volume (30 Days) | 215.9K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $5.69 |
| Revenue Next Year | N/A | $12.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $8.46 | $12.26 |
| 52 Week High | $9.95 | $29.65 |
| Indicator | ETW | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 45.28 |
| Support Level | $8.46 | $14.66 |
| Resistance Level | $9.57 | $18.13 |
| Average True Range (ATR) | 0.13 | 1.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.77 | 33.02 |
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.